Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S)

被引：0
|
作者：
Jonasch, Eric
Hasanov, Elshad
Motzer, Robert J.
Hariharan, Subramanian
Choueiri, Toni K.
Huang, Bo
Haanen, John B. A. G.
Albiges, Laurence
Venugopal, Balaji
Schmidinger, Manuela
Larkin, James M. G.
Grimm, Marc-Oliver
Negrier, Sylvie
Wang, Jing
Mariani, Mariangela
Chudnovsky, Aleksander
di Pietro, Alessandra
Rini, Brian I.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Pfizer Inc, New York, NY USA
[4] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Boston, MA USA
[6] Pfizer Inc, Groton, CT 06340 USA
[7] Netherlands Canc Inst, Amsterdam, Netherlands
[8] Inst Gustave Roussy, Villejuif, France
[9] Univ Glasgow, Glasgow, Lanark, Scotland
[10] Med Univ Vienna, Vienna, Austria
[11] Royal Marsden NHS Fdn Trust, London, England
[12] Jena Univ Hosp, Jena, Germany
[13] Univ Lyon, Ctr Leon Berard, Lyon, France
[14] Pfizer Inc, Cambridge, MA USA
[15] Pfizer SRL, Milan, Italy
[16] Cleveland Clin, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
687
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A plus Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)
    Albiges, L.
    Rini, B. I.
    Haanen, J. B. A. G.
    Motzer, R. J.
    Kollmannsberger, C. K.
    Negrier, S.
    Nole, F.
    Bedke, J.
    Bilen, M. A.
    Nathan, P.
    Tomita, Y.
    Huang, B.
    Ching, K. A.
    Chudnovsky, A.
    Robbins, P. B.
    di Pietro, A.
    Thomaidou, D.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
    Haanen, J. B. A. G.
    Larkin, J.
    Choueiri, T. K.
    Albiges, L.
    Rini, B. I.
    Atkins, M. B.
    Schmidinger, M.
    Penkov, K.
    Michelon, E.
    Wang, J.
    Mariani, M.
    di Pietro, A.
    Motzer, R. J.
    ESMO OPEN, 2023, 8 (03)
  • [33] C-reactive protein (CRP) as a predictive marker for outcomes with avelumab plus axitinib (A plus Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101.
    Tomita, Yoshihiko
    Motzer, Robert J.
    Choueiri, Toni K.
    Rini, Brian I.
    Uemura, Hirotsugu
    Oya, Mototsugu
    Albiges, Laurence
    Fujii, Yosuke
    Umeyama, Yoshiko
    Huang, Bo
    Di Pietro, Alessandra
    Schmidinger, Manuela
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [34] Potential impact of avelumab plus axitinib (A plus Ax) on tumor size (TS) compared with historical data of sunitinib (S) as evaluated by a modeling and simulation (MS) approach
    Zheng, J.
    Chang, A.
    Larkin, J.
    Motzer, R. J.
    Amantea, M.
    Bello, C.
    Pavlov, D.
    Geraldes, M.
    Martignoni, M.
    Di Pietro, A.
    Andrews, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
    Tomita, Y.
    Larkin, J.
    Venugopal, B.
    Haanen, J.
    Kanayama, H.
    Eto, M.
    Grimm, M-O
    Fujii, Y.
    Umeyama, Y.
    Huang, B.
    Mariani, M.
    di Pietro, A.
    Choueiri, T. K.
    ESMO OPEN, 2022, 7 (05)
  • [36] Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Rini, Brian I.
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem
    Hawkins, Robert
    Nosov, Dmitry
    Pouliot, Frederic
    Alekseev, Boris
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Kryzhanivska, Anna
    Bondarenko, Igor
    Azevedo, Sergio J.
    Borchiellini, Delphine
    Szczylik, Cezary
    Markus, Maurice
    McDermott, Raymond S.
    Bedke, Jens
    Tartas, Sophie
    Chang, Yen-Hwa
    Tamada, Satoshi
    Shou, Qiong
    Perini, Rodolfo F.
    Chen, Mei
    Atkins, Michael B.
    Powles, Thomas
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1116 - 1127
  • [37] Avelumab D axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
    Choueiri, T. K.
    Penkov, K.
    Uemura, H.
    Campbell, M. T.
    Pal, S.
    Kollmannsberger, C.
    Lee, J. L.
    Venugopal, B.
    Eertwegh, A. J. M. van den
    Negrier, S.
    Gurney, H.
    Albiges, L.
    Berger, R.
    Haanen, J. B. A. G.
    Juarez, V. Oyervides
    Rini, B. I.
    Larkin, J.
    Nole, F.
    Schmidinger, M.
    Atkins, M. B.
    Tomita, Y.
    Ellers-Lenz, B.
    Hoffman, J.
    Sandner, R.
    Wang, J.
    di Pietro, A.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2025, 36 (04) : 387 - 392
  • [38] A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
    Lu, Peiyao
    Liang, Weiting
    Li, Jiahao
    Hong, Yanming
    Chen, Zhuojia
    Liu, Tao
    Dong, Pei
    Huang, Hongbing
    Zhang, Tiantian
    Jiang, Jie
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [39] A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma
    Shay, Rebecca
    Nicklawsky, Andrew
    Gao, Dexiang
    Lam, Elaine T.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 370 - +
  • [40] Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Teh, Jiasian
    Narasimhan, Vignesh
    Schultz, Stephen
    Sathianathen, Niranjan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2019, 76 (01) : 126 - 127
12345